Ignite Creation Date:
2024-05-06 @ 3:10 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04547621
Status:
UNKNOWN
Last Update Posted:
2020-09-14
First Post:
2020-09-07
Brief Title:
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
Sponsor:
Huashan Hospital
Organization:
Huashan Hospital
Study Overview
Official Title:
The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme A Prospective Single-Center Single-Arm Phase II Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HSCK-010
Brief Summary:
This study aims to evaluate the safety and effectiveness of the combination of 30Gy5fx HSRT and 20Gy10fx IMRT adjuvant therapy The total biological effective dose BED of the PTV is 72 Gy in a ratio of alphabeta ratio of 3 which equals to the conventional 60Gy30fx treatment This study can provide evidence for future non-inferiority phase III randomized controlled trials The abbreviated course of radiotherapy can reduce the treatment time by half benefit patients and utilize the health resource
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None